Uvisa Health ApS

Egen beskrivelse på virk.dk

Description of key activities of the companyAs in previous years, the Company’s activities consisted of research and experimental development within the natural sciences and engineering, with a continued focus on developing medical device technology for the treatment of vaginal infections. During 2025, the Company made significant operational progress in advancing its product development, clinical evidence strategy and digital health capabilities. The primary achievement of the year was the initiation and substantial execution of the Company’s first-in-human clinical investigation at Odense University Hospital. The investigation was conducted in collaboration with clinical partners and under the oversight of the appointed Principal Investigator. By October 2025, the study was well underway and showed positive mid-point indications, supporting continued development of the Company’s technology and clinical strategy. In parallel with the clinical investigation, the Company continued to develop its connected product platform. During the year, the Company developed its first mobile application MVP capable of controlling the device. This represented an important step towards an integrated product experience and provides a foundation for future usability testing, patient interaction and digital product development. The Company also developed an initial proprietary symptom-assessment algorithm. The algorithm has not yet been clinically validated and is not currently intended to provide diagnosis, nor has it yet been released. However, it represents a foundation for structured user data capture and may support future development of data-driven user guidance, decision-support and diagnostic capabilities, subject to further development, validation and regulatory considerations. During 2025, the Company also strengthened its external profile through a visual rebrand and increased marketing and communications activity. These activities were undertaken to improve the Company’s positioning, stakeholder engagement and visibility ahead of future fundraising, clinical and commercial milestones. As part of this work, the Company increased its LinkedIn presence by more than 2,000 followers during the year. Management also continued fundraising preparations and investor dialogue during 2025 to support the Company’s next phase of development.